NCT02034227View on ClinicalTrials.gov

Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Acute Myeloid LeukemiaChronic Lymphocytic Leukemia
Interventions
DRUG

SG2000

intravenous doses given on Days 1, 2, and 3 of each 21-day cycle (1 to 6 cycles).

Trial Locations (2)

27705

Duke University, Durham

29425

Medical University of South Carolina, Charleston

Sponsors

Lead Sponsor

Spirogen
All Listed Sponsors
lead

Spirogen

INDUSTRY